Detalles de la búsqueda
1.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 390(14): 1265-1276, 2024 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38598794
2.
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
N Engl J Med
; 388(18): 1657-1667, 2023 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37133585
3.
Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial.
Support Care Cancer
; 32(2): 91, 2024 Jan 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38194162
4.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(9): 989-1001, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37591293
5.
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Cancer
; 129(1): 118-129, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36308296
6.
Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial.
Support Care Cancer
; 32(1): 34, 2023 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38103088
7.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(4): 465-478, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35298906
8.
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Lancet
; 397(10274): 592-604, 2021 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581821
9.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1116-1127, 2019 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30779529
10.
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
N Engl J Med
; 381(7): 626-636, 2019 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31166680
11.
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Breast Cancer Res Treat
; 191(3): 565-576, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34860318
12.
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(5): 678-689, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33848462
13.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 22(1): 51-65, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33285097
14.
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
Int J Cancer
; 148(10): 2557-2570, 2021 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33348420
15.
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 379(20): 1926-1936, 2018 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30345905
16.
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 188(2): 369-377, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34125340
17.
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(10): 1269-1282, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32861273
18.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet
; 393(10183): 1819-1830, 2019 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30955977
19.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Lancet
; 394(10212): 1929-1939, 2019 11 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31590988
20.
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Breast Cancer Res Treat
; 183(2): 419-428, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32683565